XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 53.5

Change

0.00 (0.00)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.50 (+1.85%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.88 (+1.73%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.96 (+1.09%)

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.98 (+1.78%)

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+4.25 (+1.78%)

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.05B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.41 (+1.45%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+1.21 (+1.24%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.09 (-1.11%)

USD 40.74B
0ZC:F Zscaler Inc

+0.20 (+0.13%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.62% 56% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.62% 53% F 55% F
Trailing 12 Months  
Capital Gain 9.54% 51% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.54% 49% F 54% F
Trailing 5 Years  
Capital Gain 61.27% 80% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.27% 80% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 10.63% 80% B- 74% C
Dividend Return 10.63% 78% C+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 61% D- 84% B
Risk Adjusted Return 99.59% 98% N/A 96% N/A
Market Capitalization 0.85B 71% C- 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike